Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro

Virology

Volumn 363, Issue 2, 2007, Pages 447-453

  Quakkelaar, Esther D ^a   Bunnik, Evelien M ^a   van Alphen, Floris P J ^a   Boeser Nunnink, Brigitte D M ^a   van Nuenen, Ad C ^a   Schuitemaker, Hanneke ^a  

^a SANQUIN RESEARCH   (Netherlands)

Author keywords

Broadly neutralizing antibodies; Escape; HIV 1; Replicative capacity

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY G12; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIBODIES, MONOCLONAL; DRUG RESISTANCE, VIRAL; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; NEUTRALIZATION TESTS; VARIATION (GENETICS); VIRULENCE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34249029693     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.02.011     Document Type: Article

References (42)

1. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nystrom G., and Fenyö E.M. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4 (1990) 107-112
2. Arendrup M., Nielsen C., Hansen J.E.S., Pedersen C., Mathiesen L., and Nielsen J.O. Autologous HIV-1 neutralizing antibodies: emergence of neutralization resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquired Immune Defic. Syndr. 5 (1992) 303-307
3. Beaumont T., Quakkelaar E., van Nuenen A., Pantophlet R., and Schuitemaker H. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. J. Virol. 78 (2004) 5651-5657
4. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004) 13232-13252
5. Blaak H., Brouwer M., Ran L.J., De Wolf F., and Schuitemaker H. In vitro replication kinetics of HIV-1 variants in relation to viral load in long-term survivors of HIV-1 infection. J. Infect. Dis. 177 (1998) 600-610
6. Blaak H., Van 't Wout A.B., Brouwer M., Cornelissen M., Kootstra N.A., Albrecht-van Lent N., Keet R.P.M., Goudsmit J., Coutinho R.A., and Schuitemaker H. Infectious cellular load in HIV-1-infected individuals and susceptibility of PBMC from their exposed partners to NSI HIV-1 as major determinants for HIV-1 transmission in homosexual couples. J. Virol. 72 (1998) 218-224
7. Bradney A.P., Scheer S., Crawford J.M., Buchbinder S.P., and Montefiori D.C. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J. Infect. Dis. 179 (1999) 1264-1267
8. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W.H., Sawyer L.S.W., Hendry R.M., Dunlop N., Nara P.L., Lamacchia M., Garratty E.M., Stiehm E.R., Bryson Y.J., Cao Y., Moore J.P., Ho D.D., and Barbas III C.F. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 (1994) 1024-1027
9. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., Dwek R.A., Katinger H., Burton D.R., and Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 (2003) 2065-2071
10. Conley A.J., Gorny M.K., Kessler J.A., Boots L.J., Ossorio-Castro M., Koenig S., Lineberger D.W., Emini E.A., Williams C., and Zolla-Pazner S. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68 (1994) 6994-7000
11. Conley A.J., Kessler J.A., Boots L.J., Tung J.S., Arnold B.A., Keller P.M., Shaw A.R., and Emini E.A. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3348-3352
12. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., and Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 (2004) 2019-2022
13. Frost S.D., Liu Y., Pond S.L., Chappey C., Wrin T., Petropoulos C.J., Little S.J., and Richman D.D. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J. Virol. 79 (2005) 6523-6527
14. Kwa D., Vingerhoed J., Boeser-Nunnink B., and Schuitemaker H. Increased in-vitro cytopathicity of CCR5 restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J. Infect. Dis. 187 (2003) 1397-1403
15. Lange J.M.A., Boucher C.A.B., Hollak C.E.M., Wiltink E.H.H., Reiss P., Van Royen E.A., Roos M.Th.L., Danner S.A., and Goudsmit J. Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N. Engl. J. Med. 322 (1990) 1375-1377
16. Martinez-Picado J., Prado J.G., Fry E.E., Pfafferott K., Leslie A., Chetty S., Thobakgale C., Honeyborne I., Crawford H., Matthews P., Pillay T., Rousseau C., Mullins J.I., Brander C., Walker B.D., Stuart D.I., Kiepiela P., and Goulder P. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80 (2006) 3617-3623
17. Miller M.D., Geleziunas R., Bianchi E., Lennard S., Hrin R., Zhang H., Lu M., An Z., Ingallinella P., Finotto M., Mattu M., Finnefrock A.C., Bramhill D., Cook J., Eckert D.M., Hampton R., Patel M., Jarantow S., Joyce J., Ciliberto G., Cortese R., Lu P., Strohl W., Schleif W., McElhaugh M., Lane S., Lloyd C., Lowe D., Osbourn J., Vaughan T., Emini E., Barbato G., Kim P.S., Hazuda D.J., Shiver J.W., and Pessi A. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 14759-14764
18. Montefiori D.C., Hill T.S., Vo H.T., Walker B.D., and Rosenberg E.S. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75 (2001) 10200-10207
19. Montefiori D.C., Altfeld M., Lee P.K., Bilska M., Zhou J., Johnston M.N., Gao F., Walker B.D., and Rosenberg E.S. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J. Immunol. 170 (2003) 3906-3914
20. Moog C., Fleury H.J.A., Pellegrin I., Kirn A., and Aubertin A.M. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71 (1997) 3734-3741
21. Moore J.P., Cao Y., Qing L., Sattentau Q.J., Pyati J., Koduri R., Robinson J., Barbas III C.F., Burton I.I.I., and Ho D.R. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69 (1995) 101-109
22. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X., Binley J.M., Zhang M.Y., Sidorov I.A., Broder C.C., Robinson J., Parren P.W., Burton D.R., and Dimitrov D.S. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 6913-6918
23. Parren P.W.H.I., Wang M., Trkola A., Binley J.M., Purtscher M., Katinger H., Moore J.P., and Burton D.R. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J. Virol. 72 (1998) 10270-10274
24. Parren P.W.H.I., Moore J.P., Burton D.R., and Sattentau Q.J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13 Suppl. A (1999) S137-S162
25. Pilgrim A.K., Pantaleo G., Cohen O.J., Fink L.M., Zhou J.Y., Zhou J.T., Bolognesi D.P., Fauci A.S., and Montefiori D.C. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176 (1997) 924-932
26. Poignard P., Saphire E.O., Parren P.W., and Burton D.R. gp120: biologic aspects of structural features. Annu. Rev. Immunol. 19 (2001) 253-274
27. Repits J., Oberg M., Esbjornsson J., Medstrand P., Karlsson A., Albert J., Fenyo E.M., and Jansson M. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J. Gen. Virol. 86 (2005) 2859-2869
28. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4144-4149
29. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., and Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76 (2002) 7293-7305
30. Scanlan C.N., Pantophlet R., Wormald M.R., Ollman Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., and Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alfa1 → 2 mannose residues on the outer face of gp120. J. Virol. 76 (2002) 7306-7321
31. Schuitemaker H., Koot M., Kootstra N.A., Dercksen M.W., De Goede R.E.Y., Van Steenwijk R.P., Lange J.M.A., Eeftink Schattenkerk J.K.M., Miedema F., and Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66 (1992) 1354-1360
32. Tersmette M., Winkel I.N., Groenink M., Gruters R.A., Spence P., Saman E., van der Groen G., Miedema F., and Huisman J.G. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology 171 (1989) 149-155
33. Trachtenberg J.D., and Sande M.A. Emerging resistance to nonnucleoside reverse transcriptase inhibitors: a warning and a challenge. JAMA 288 (2002) 239-241
34. Tremblay M., and Wainberg M.A. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J. Infect. Dis. 162 (1990) 735-737
35. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas III C.F., Burton D.R., Ho D.D., and Moore J.P. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69 (1995) 6609-6617
36. Troyer R.M., Collins K.R., Abraha A., Fraundorf E., Moore D.M., Krizan R.W., Toossi Z., Colebunders R.L., Jensen M.A., Mullins J.I., Vanham G., and Arts E.J. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J. Virol. 79 (2005) 9006-9018
37. Van 't Wout A.B., Kootstra N.A., Mulder-Kampinga G.A., Albrecht-van Lent N., Scherpbier H.J., Veenstra J., Boer K., Coutinho R.A., Miedema F., and Schuitemaker H. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral and vertical transmission. J. Clin. Invest. 94 (1994) 2060-2067
38. Van 't Wout A.B., Blaak H., Ran L.J., Brouwer M., Kuiken C., and Schuitemaker H. Evolution of syncytium inducing and non-syncytium inducing biological virus clones in relation to replication kinetics during the course of HIV-1 infection. J. Virol. 72 (1998) 5099-5107
39. Veenstra J., Schuurman R., Cornelissen M., Van 't Wout A.B., Boucher C.A.B., Schuitemaker H., Goudsmit J., and Coutinho R.A. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection with blood of a patient with AIDS: characteristics and natural history of the virus. Clin. Infect. Dis. 21 (1995) 556-560
40. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
41. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Ollman Saphire E., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W.H.I. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 (2001) 10892-10905
42. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., and Burton D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79 (2005) 1252-1261